TY - JOUR
T1 - Hyaluronan-modified nanoparticles for tumor-targeting
AU - Sakurai, Yu
AU - Harashima, Hideyoshi
N1 - Funding Information:
This study was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (Grant No. 18K18351) and by The Mochida Memorial Foundation for Medical and Pharmaceutical Research and Terumo Life Science Foundation and the Special Education and Research Expenses of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. The authors wish to thank Dr. Milton S Feather for appropriately modifying the manuscript.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/9/2
Y1 - 2019/9/2
N2 - Introduction: Hyaluronan (HA), a natural polysaccharide, is produced in large amounts by the human body. Since its receptor CD44 is highly expressed in many types of cancers, HA is a promising ligand for cancer-targeting nanoparticles (NPs). Since the enhanced permeability and retention (EPR) effect-based strategy faces difficulties in terms of efficiency in clinical studies, studies focusing on HA-modified NPs that can actively target cancer cells should be prominent for further progress in NP-based cancer treatment. Areas covered: Various materials combined with HA composed of lipid nanoparticles and polymers as well as iron, gold and other metals have been examined. In addition, their cargos have been quite diverse and include small molecule drugs, imaging agents, proteins and nucleic acids. We summarize recent studies on varieties of NPs and describe the properties of HA as a ligand of CD44. Expert opinion: In spite of a number of studies on HA-based NPs, there is few examples of HA-based NPs in clinical. In order to make a progress in clinical study, an evaluation methodology of HA-NPs should be unified and normalized.
AB - Introduction: Hyaluronan (HA), a natural polysaccharide, is produced in large amounts by the human body. Since its receptor CD44 is highly expressed in many types of cancers, HA is a promising ligand for cancer-targeting nanoparticles (NPs). Since the enhanced permeability and retention (EPR) effect-based strategy faces difficulties in terms of efficiency in clinical studies, studies focusing on HA-modified NPs that can actively target cancer cells should be prominent for further progress in NP-based cancer treatment. Areas covered: Various materials combined with HA composed of lipid nanoparticles and polymers as well as iron, gold and other metals have been examined. In addition, their cargos have been quite diverse and include small molecule drugs, imaging agents, proteins and nucleic acids. We summarize recent studies on varieties of NPs and describe the properties of HA as a ligand of CD44. Expert opinion: In spite of a number of studies on HA-based NPs, there is few examples of HA-based NPs in clinical. In order to make a progress in clinical study, an evaluation methodology of HA-NPs should be unified and normalized.
KW - CD44
KW - hyaluronan
KW - inorganic
KW - lipid nanoparticles
KW - Nanoparticles
KW - polymer
UR - http://www.scopus.com/inward/record.url?scp=85070507417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070507417&partnerID=8YFLogxK
U2 - 10.1080/17425247.2019.1645115
DO - 10.1080/17425247.2019.1645115
M3 - Review article
C2 - 31387408
AN - SCOPUS:85070507417
SN - 1742-5247
VL - 16
SP - 915
EP - 936
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 9
ER -
